fingolimod Oral Capsule [Gilenya]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The introduction of oral disease modifying therapies has transformed the treatment landscape for patients with multiple sclerosis…
Cardiac arrhythmias and ECG abnormalities including bradycardia, prolongation of the QT interval, and atrioventricular (AV…
The compound dimethyl fumarate (DMF) has been an approved drug in Europe for several decades as a therapeutic for psoriasis and…
Introduccion. Se describe el diseno de un registro electronico de los pacientes con esclerosis multiple que inician tratamiento…
INTRODUCTION
This study outlines the design of an electronic register of patients with multiple sclerosis who began treatment…
In multiple sclerosis, conduction block in demyelinated axons underlies early neurological symptoms, whereas axonal transection…
Sphingosine 1-phosphate (S1P), a lysophospholipid mediator, is generated from sphingosine by sphingosine kinases and binds five…
Abstract Objective: To assess the costs of oral treatment with Gilenya® (fingolimod) compared to intravenous infusion of Tysabri…
Objective: In order to investigate the safety and efficacy of fingolimod (Gilenya®) in everyday clinical practice, a 4000-patient…